Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 10/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12794000 | 0.79 | ACHE (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14979149 | 0.79 | LMNA (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL24793816 | 0.76 | CHRM1 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12376552 | 0.75 | HTT (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12376567 | 0.75 | CHRM1 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20927591 | 0.74 | LMNA (0.59) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22725674 | 0.74 | LMNA (0.52) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20649067 | 0.74 | LMNA (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2284333 | 0.73 | BCHE (0.47) | — | |
| SCHEMBL1308650 | 0.73 | HRH3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | CHRM2 3376/4885CHRM4 4086/4885CHRM5 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.